VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
MCKMcKesson Corporation
$763.51$91.8B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksMCKFinancials

McKesson Corporation (MCK) Financials

30Y historyFree accessUpdated daily

Revenue growth remains highly variable, ranging from 6.0% to 23.4% year-over-year, while operating margins remain structurally thin, peaking at only 2.3% in 2026Q4.

MCK Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricMar'26Mar'25Mar'24Mar'23Mar'22Mar'21Mar'20Mar'19Mar'18Mar'17Mar'16Mar'15Mar'14Mar'13Mar'12Mar'11Mar'10Mar'09Mar'08Mar'07Mar'06Mar'05Mar'04Mar'03Mar'02Mar'01Mar'00Mar'99Mar'98Mar'97
Sales/Revenue403.43B359.05B308.95B276.71B263.97B238.23B231.05B214.32B208.36B198.53B190.88B179.04B137.61B122.45B122.73B112.08B108.7B106.63B101.7B92.98B88.05B80.51B69.51B57.12B50.01B42.01B36.73B30.38B20.86B12.89B
Revenue Growth %12.36%16.22%11.65%4.83%10.8%3.11%7.81%2.86%4.95%4.01%6.61%30.11%12.38%-0.23%9.5%3.11%1.94%4.85%9.39%5.6%9.36%15.84%21.68%14.23%19.03%14.36%20.91%45.67%61.85%-6.05%
Cost of Goods Sold388.88B346.57B296.75B264.84B251.32B226.65B219.65B203.56B197.97B187.84B179.94B168.12B129.57B115.7B116.31B106.09B103.02B101.25B96.7B88.64B83.21B76.67B66.26B54.02B47.21B39.58B34.21B27.52B19.25B11.78B
COGS % of Revenue96.39%96.52%96.05%95.71%95.21%95.14%95.07%94.98%95.01%94.62%94.27%93.9%94.16%94.49%94.76%94.65%94.77%94.95%95.08%95.34%94.5%95.23%95.33%94.57%94.41%94.21%93.13%90.57%92.29%91.39%
Gross Profit14.55B12.48B12.2B11.87B12.65B11.58B11.4B10.76B10.39B10.69B10.94B10.93B8.04B6.75B6.43B5.99B5.68B5.38B5B4.34B3.78B3.45B3.25B3.1B2.8B2.43B2.52B2.86B1.61B1.11B
Gross Margin %3.61%3.48%3.95%4.29%4.79%4.86%4.93%5.02%4.99%5.38%5.73%6.1%5.84%5.51%5.24%5.35%5.23%5.05%4.92%4.66%4.29%4.28%4.67%5.43%5.59%5.79%6.87%9.43%7.71%8.61%
Gross Profit Growth %16.54%2.32%2.81%-6.17%9.21%1.6%5.93%3.56%-2.77%-2.33%0.13%35.97%19.06%5.04%7.28%5.46%5.54%7.66%15.29%14.83%9.48%6.21%4.7%10.93%15.05%-3.67%-11.91%78.11%45.03%-8.96%
Operating Expenses8.1B8.11B8.28B7.42B9.93B8.07B8.39B7.68B7.47B7.33B7.09B7.4B5.39B4.33B4.05B3.89B3.67B3.66B3.52B3.05B2.61B2.44B2.26B2.17B2.1B2.33B2.37B2.53B1.25B1.02B
OpEx % of Revenue2.01%2.26%2.68%2.68%3.76%3.39%3.63%3.59%3.59%3.69%3.72%4.13%3.92%3.54%3.3%3.47%3.38%3.43%3.46%3.28%2.96%3.04%3.26%3.8%4.21%5.56%6.44%8.34%5.98%7.89%
Selling, General & Admin-8.1B8.02B8.2B7.33B9.86B8B8.29B7.61B7.35B6.99B6.7B7.01B4.93B3.85B3.61B3.49B3.29B3.3B3.17B2.77B2.38B2.26B2.09B2.02B1.95B2.08B2.05B2.22B1.16B944.5M
SG&A % of Revenue-2.01%2.23%2.65%2.65%3.73%3.36%3.59%3.55%3.53%3.52%3.51%3.91%3.58%3.14%2.94%3.11%3.03%3.09%3.12%2.98%2.71%2.81%3.01%3.54%3.89%4.94%5.58%7.3%5.56%7.33%
Research & Development103M91M77M89M70M74M96M71M125M341M392M392M456M480M440M407M376M364M347M284M223M182M172.7M149.4M135.1M147.5M112.6M114.7M00
R&D % of Revenue0.03%0.03%0.02%0.03%0.03%0.03%0.04%0.03%0.06%0.17%0.21%0.22%0.33%0.39%0.36%0.36%0.35%0.34%0.34%0.31%0.25%0.23%0.25%0.26%0.27%0.35%0.31%0.38%--
Other Operating Expenses16.09B0000000000000000000000022M111.6M201.3M199.3M87.2M71.8M
Operating Income6.45B4.37B3.93B4.45B2.72B3.51B3.01B3.08B2.92B3.36B3.85B3.53B2.65B2.42B2.38B2.1B2.01B1.72B1.48B1.28B1.17B1B983.4M929.9M693.6M96.4M158.2M332.2M362.2M92.8M
Operating Margin %1.6%1.22%1.27%1.61%1.03%1.47%1.3%1.44%1.4%1.69%2.02%1.97%1.93%1.98%1.94%1.87%1.85%1.61%1.45%1.38%1.33%1.25%1.41%1.63%1.39%0.23%0.43%1.09%1.74%0.72%
Operating Income Growth %47.62%11.33%-11.81%63.53%-22.42%16.53%-2.14%5.37%-12.99%-12.83%9.06%33.25%9.5%1.68%13.44%4.38%16.72%16.51%15.11%9.65%16.52%2.2%5.75%34.07%619.5%-39.06%-52.38%-8.28%290.3%-66.14%
EBITDA7.18B5.01B4.56B5.31B3.72B4.73B3.93B4.03B3.87B4.27B4.74B4.55B3.35B3.01B2.93B2.59B2.48B2.16B1.85B1.58B1.43B1.25B1.22B1.13B901.1M342.5M359.5M531.5M449.4M164.6M
EBITDA Margin %1.78%1.39%1.48%1.92%1.41%1.99%1.7%1.88%1.86%2.15%2.48%2.54%2.44%2.46%2.39%2.31%2.29%2.03%1.82%1.7%1.63%1.56%1.75%1.98%1.8%0.82%0.98%1.75%2.15%1.28%
EBITDA Growth %43.43%9.78%-14.09%42.59%-21.29%20.26%-2.31%4%-9.26%-9.9%4.13%35.6%11.39%2.73%12.99%4.43%14.84%16.98%17.1%10.19%14.27%3.17%7.22%25.8%163.09%-4.73%-32.36%18.27%173.03%-52.35%
D&A (Non-Cash Add-back)729M636M635M857M1B1.22B922M949M951M910M885M1.02B704M591M551M496M474M441M371M295M262M249M232.1M203.7M207.5M246.1M201.3M199.3M87.2M71.8M
EBIT6.45B4.62B4.03B4.88B2.11B-4.82B1.39B874M522M7.2B3.6B3.03B2.35B2.15B2.17B1.83B2.05B1.21B1.6B1.4B1.26B-127M978M929.9M698.5M204.9M109.5M110.4M562.5M232.2M
Net Interest Income-68M-83M-125M-141M-168M-205M-200M-225M-235M-279M-335M-354M-234M-207M-232M-179M-171M-113M-53M4M11M-77M00000000
Interest Income179M173M118M107M10M12M49M39M48M29M18M20M23M22M19M18M16M31M89M103M105M41M00000000
Interest Expense247M256M243M248M178M217M249M264M283M308M353M374M257M229M251M197M187M144M142M99M94M118M00000000
Other Income/Expense-253M-13M-138M177M-795M-8.54B-1.87B-2.47B-2.68B3.53B-601M-874M-554M-501M-461M-463M-146M-658M-21M13M0-1.25B-72M-74.5M-87.5M-196.3M148.7M-130.2M-109.4M-61.7M
Pretax Income6.2B4.36B3.79B4.63B1.93B-5.03B1.14B610M239M6.89B3.25B2.66B2.1B1.92B1.92B1.64B1.86B1.06B1.46B1.3B1.17B-245M911.4M855.4M601.2M9.6M306.9M202M253.5M36.4M
Pretax Margin %1.54%1.21%1.23%1.67%0.73%-2.11%0.5%0.28%0.11%3.47%1.7%1.48%1.52%1.57%1.56%1.46%1.71%1%1.43%1.4%1.33%-0.3%1.31%1.5%1.2%0.02%0.84%0.66%1.22%0.28%
Income Tax1.1B878M629M905M636M-695M18M356M-53M1.61B908M815M742M581M516M505M601M241M468M329M421M-83.1M264.9M293.3M182.6M52.3M122.3M117.1M98.6M31.3M
Effective Tax Rate %17.77%20.14%16.6%19.55%32.99%13.81%1.57%58.36%-22.18%23.42%27.94%30.67%35.4%30.28%26.89%30.89%32.24%22.65%32.12%25.37%35.95%33.92%29.07%34.29%30.37%544.79%39.85%57.97%38.9%85.99%
Net Income4.76B3.29B3B3.56B1.11B-4.54B900M34M67M5.18B2.26B1.48B1.26B1.34B1.4B1.13B1.26B823M990M963M738M-157M646.5M555.4M418.6M-48.3M723.7M84.9M154.9M133.9M
Net Margin %1.18%0.92%0.97%1.29%0.42%-1.91%0.39%0.02%0.03%2.61%1.18%0.82%0.92%1.09%1.14%1.01%1.16%0.77%0.97%1.04%0.84%-0.19%0.93%0.97%0.84%-0.11%1.97%0.28%0.74%1.04%
Net Income Growth %44.52%9.76%-15.67%219.57%124.54%-604.33%2547.06%-49.25%-98.71%129.54%52.98%16.86%-5.61%-4.63%24.16%-10.53%53.46%-16.87%2.8%30.49%570.06%-124.28%16.4%32.68%966.67%-106.67%752.41%-45.19%15.68%-1.11%
Net Income (Continuing)5.1B3.48B3.16B3.73B1.29B-4.34B1.13B254M292M5.28B2.34B1.84B1.41B1.36B1.4B1.13B1.26B823M989M968M745M-160M643M562.1M421.8M-43.3M184.6M60.6M275.2M83.3M
Discontinued Operations000-3M-5M-1M-6M1M5M-11M-32M-299M-96M000001M-5M-7M3M00000000
Minority Interest1.34B380M372M367M480M1.47B1.62B1.59B1.71B1.5B1.49B1.47B1.8B0000000000196.3M196.1M195.9M195.8M195.6M195.4M194.8M
EPS (Diluted)38.3825.7222.3925.047.23-27.024.950.170.3222.739.706.275.415.595.594.574.622.953.322.992.38-0.532.191.881.43-0.172.550.311.620.80
EPS Growth %49.22%14.87%-10.58%246.33%126.76%-645.86%2811.76%-46.88%-98.59%134.33%54.7%15.9%-3.22%0%22.32%-1.08%56.61%-11.14%11.04%25.63%549.06%-124.2%16.49%31.47%941.18%-106.67%722.58%-80.86%102.5%-44.83%
EPS (Basic)38.5525.8622.5425.237.31-27.024.970.170.3222.959.826.375.515.715.704.654.702.993.403.062.46-0.532.231.921.47-0.172.570.311.660.83
Diluted Shares Outstanding124.1M128.1M134.1M142.2M154.1M160.6M182M197.3M209M223M233M235M233M239M251M263M273M279M298M305M316M294M299M298.8M298.1M283.1M284.2M275.2M95.61M84.39M
Basic Shares Outstanding123.6M127.4M133.2M141.1M152.3M160.6M181M196.3M208M221M230M232M229M235M246M258M269M275M291M298M306M294M290M289.3M285.2M283.1M281.3M275.2M93.44M83.65M
Dividend Payout Ratio8%10.47%10.46%8.2%24.87%-32.67%858.82%391.04%4.88%10.81%15.38%16.94%14.5%13.9%15.13%10.37%14.09%7.07%7.48%9.89%-10.8%14.35%18.75%-10.71%111.66%29.89%38.76%

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowRobust
Top Statement Risk

Regulatory drug pricing reform

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q4)

Revenue Volatility Amid Strategic Realignment

As indicated by recent quarterly filings, McKesson's top-line growth has exhibited significant variability, ranging from 6.0% to 23.4% year-over-year, reflecting the company's ongoing transition toward higher-margin domestic specialty markets and the divestiture of lower-margin international operations that previously anchored the firm's historical revenue base.

The wide fluctuations in quarterly revenue suggest that the company is still absorbing the impact of its portfolio restructuring. Investors should monitor whether the current revenue trajectory stabilizes as the firm pivots further into the US Oncology Network and specialized biopharma services.

Structural Constraints on Operating Profitability

According to the provided financial data, McKesson maintains a structurally thin operating margin profile, which fluctuated between 0.8% and 2.3% over the last ten quarters, underscoring the inherent difficulty of scaling profitability within a high-volume, low-margin pharmaceutical distribution model that is highly sensitive to operational costs.

The narrow margin spread suggests that even minor inflationary pressures in logistics or labor can disproportionately impact bottom-line results. The recent expansion toward 2.3% in 2026Q4 may indicate successful mix-shifting, though this remains subject to the volatility of pharmaceutical procurement costs.

Operating Leverage Remains Highly Constrained

Based on reported figures, McKesson's operating income has not consistently scaled faster than gross profit, as evidenced by the erratic operating margin performance that frequently tracks closely with gross margin fluctuations, suggesting limited operating leverage within the current high-throughput, capital-intensive pharmaceutical distribution infrastructure.

The lack of significant operating leverage implies that the company's SG&A expenses are largely fixed and necessary to support the massive scale of its distribution network. Future margin expansion likely depends on the successful integration of higher-margin technology services rather than traditional distribution volume growth.

Earnings Volatility Masks Underlying Performance

As documented in the income statement history, EPS has experienced extreme swings, including a 66.6% increase in 2025Q4 followed by a 62.3% decline in 2025Q2, which suggests that reported net income is frequently impacted by non-operating items, legal accruals, or accounting adjustments rather than pure operational output.

The inconsistency in EPS growth warrants further investigation into the specific non-recurring charges that have historically clouded the company's true earnings power. Analysts should focus on normalized earnings metrics to better assess the sustainability of the firm's profitability in the face of ongoing legal and regulatory headwinds.

MCK — Frequently Asked Questions

Quick answers to the most common questions about buying MCK stock.

What was McKesson Corporation's (MCK) revenue in 2026?

For fiscal year 2026, McKesson Corporation (MCK) reported total revenue of $403.43B. This represents a 3030.6% increase compared to $12.89B in 1997.

Is McKesson Corporation (MCK) profitable?

McKesson Corporation (MCK) is profitable, generating $4.76B in net income for the fiscal year ending 2026 with a net profit margin of 1.2%.

What is McKesson Corporation's operating profit margin?

McKesson Corporation (MCK) reported an operating income of $6.45B, resulting in an operating profit margin of 1.6%. This margin reflects the operational efficiency of the business before interest and taxes.

What is McKesson Corporation's gross profit and gross margin?

McKesson Corporation (MCK) generated $14.55B in gross profit for the year, representing a gross profit margin of 3.6%. This demonstrates the company's core pricing power and production efficiency.